Author: Niculet, Elena; Chioncel, Valentin; Elisei, Alina M.; Miulescu, Magdalena; Buzia, Olimpia D.; Nwabudike, Lawrence C.; Craescu, Mihaela; Draganescu, Miruna; Bujoreanu, Florin; Marinescu, Elisabeta; Arbune, Manuela; Radaschin, Diana Sabina; Bobeica, Carmen; Nechita, Aurel; Tatu, Alin L.
Title: Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review) Cord-id: 2vefeett Document date: 2021_1_25
ID: 2vefeett
Snippet: Interleukin 6 (IL-6), a cytokine produced by various cells of the human body (macrophages, lymphocytes, astrocytes, ischemic myocytes, endothelial cells) has both pro-inflammatory and anti-inflammatory properties, being a key component in regulating various physiologic and pathological processes. The structure of this molecule and the receptor system it possesses are important due to the different activities that IL-6 can exert; through trans-signaling pro-inflammatory activities are mediated, w
Document: Interleukin 6 (IL-6), a cytokine produced by various cells of the human body (macrophages, lymphocytes, astrocytes, ischemic myocytes, endothelial cells) has both pro-inflammatory and anti-inflammatory properties, being a key component in regulating various physiologic and pathological processes. The structure of this molecule and the receptor system it possesses are important due to the different activities that IL-6 can exert; through trans-signaling pro-inflammatory activities are mediated, while through classic signaling, IL-6 is responsible for anti-inflammatory and regenerative activities. IL-6 signaling is involved in coronary artery disease and the global COVID-19 pandemic. This proatherogenic cytokine reaches elevated serum levels in the cytokine storm generated by SARS-CoV-2, and is also associated with smoking or obesity-classic cardiovascular risk factors which promote inflammatory states. IL-6 levels are proportionally correlated with dyslipidemia, hypertension and glucose dysregulation, and they are associated with poor outcomes in patients with unstable angina or acute myocardial infarction. IL-6 targeting for treatment development (not only) in cardiovascular disease and COVID-19 is still a matter of ongoing research, although tocilizumab has proven to be effective in reducing the proatherogenic effects of IL-6 and is suggested to improve COVID-19 patient survival.
Search related documents:
Co phrase search for related documents- abdominal pain and acute heart failure: 1, 2
- abdominal pain and acute inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
- abdominal pain and acute lymphoblastic leukemia: 1, 2
- abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- abdominal pain and acute response: 1, 2, 3
- abdominal pain and acute syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- abdominal pain and administration insulin: 1
- abdominal pain and liver cell: 1
- abdominal pain and liver effect: 1
- abdominal pain and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- abdominal pain and liver function test: 1
- abdominal pain and liver renal: 1, 2, 3, 4
- abdominal pain and liver renal failure: 1, 2
- abdominal pain and liver resection: 1, 2, 3
- abdominal pain and long short: 1, 2, 3, 4
- abdominal pain and long short term: 1, 2, 3, 4, 5
- abdominal pain and long term short: 1, 2, 3, 4, 5
- abdominal pain and low density: 1, 2
- abdominal pain and low increase: 1, 2
Co phrase search for related documents, hyperlinks ordered by date